Selected research
Industry Research
Remicade (Infliximab) and Biosimilar Industry Research Report 2026
Market perspective
The global Remicade (Infliximab) and Biosimilar market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Remicade (Infliximab) and Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Remicade (Infliximab) and Biosimilar is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Remicade (Infliximab) and Biosimilar is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Remicade (Infliximab) and Biosimilar include J & J, Pfizer, Amgen and Organon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Remicade (Infliximab) and Biosimilar market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Remicade (Infliximab) and Biosimilar Market by Company
J & J
Pfizer
Amgen
Organon
Remicade (Infliximab) and Biosimilar Segment by Type
Brand
Biosimilar
Remicade (Infliximab) and Biosimilar Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Remicade (Infliximab) and Biosimilar Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade (Infliximab) and Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Remicade (Infliximab) and Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade (Infliximab) and Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Remicade (Infliximab) and Biosimilar manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Remicade (Infliximab) and Biosimilar by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Remicade (Infliximab) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Brand
- Biosimilar
Applications
- Ankylosing Spondylitis
- Rheumatoid Arthritis
- Crohn’s Disease
- Other
Companies covered
- J & J
- Pfizer
- Amgen
- Organon
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Remicade (Infliximab) and Biosimilar Market Size (2021-2032)
- 2.2.2 Global Remicade (Infliximab) and Biosimilar Sales (2021-2032)
- 2.2.3 Global Remicade (Infliximab) and Biosimilar Market Average Price (2021-2032)
- 2.3 Remicade (Infliximab) and Biosimilar by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Brand
- 2.3.3 Biosimilar
- 2.4 Remicade (Infliximab) and Biosimilar by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ankylosing Spondylitis
- 2.4.3 Rheumatoid Arthritis
- 2.4.4 Crohn’s Disease
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Remicade (Infliximab) and Biosimilar Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Remicade (Infliximab) and Biosimilar Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Remicade (Infliximab) and Biosimilar Revenue of Manufacturers (2021-2026)
- 3.4 Global Remicade (Infliximab) and Biosimilar Average Price by Manufacturers (2021-2026)
- 3.5 Global Remicade (Infliximab) and Biosimilar Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Remicade (Infliximab) and Biosimilar, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Remicade (Infliximab) and Biosimilar, Product Type & Application
- 3.8 Global Manufacturers of Remicade (Infliximab) and Biosimilar, Established Date
- 3.9 Global Remicade (Infliximab) and Biosimilar Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 J & J
- 4.1.1 J & J Company Information
- 4.1.2 J & J Business Overview
- 4.1.3 J & J Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 J & J Remicade (Infliximab) and Biosimilar Product Portfolio
- 4.1.5 J & J Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Remicade (Infliximab) and Biosimilar Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 Amgen
- 4.3.1 Amgen Company Information
- 4.3.2 Amgen Business Overview
- 4.3.3 Amgen Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Amgen Remicade (Infliximab) and Biosimilar Product Portfolio
- 4.3.5 Amgen Recent Developments
- 4.4 Organon
- 4.4.1 Organon Company Information
- 4.4.2 Organon Business Overview
- 4.4.3 Organon Remicade (Infliximab) and Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Organon Remicade (Infliximab) and Biosimilar Product Portfolio
- 4.4.5 Organon Recent Developments
5 Global Remicade (Infliximab) and Biosimilar Market Scenario by Region
- 5.1 Global Remicade (Infliximab) and Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021-2032
- 5.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2021-2026
- 5.2.2 Global Remicade (Infliximab) and Biosimilar Sales by Region: 2027-2032
- 5.3 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2021-2032
- 5.3.1 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2021-2026
- 5.3.2 Global Remicade (Infliximab) and Biosimilar Revenue by Region: 2027-2032
- 5.4 North America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
- 5.4.1 North America Remicade (Infliximab) and Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
- 5.4.3 North America Remicade (Infliximab) and Biosimilar Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
- 5.5.1 Europe Remicade (Infliximab) and Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
- 5.5.3 Europe Remicade (Infliximab) and Biosimilar Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
- 5.6.1 Asia Pacific Remicade (Infliximab) and Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Remicade (Infliximab) and Biosimilar Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
- 5.7.1 South America Remicade (Infliximab) and Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
- 5.7.3 South America Remicade (Infliximab) and Biosimilar Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Remicade (Infliximab) and Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Remicade (Infliximab) and Biosimilar Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Remicade (Infliximab) and Biosimilar Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2021-2032)
- 6.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Type (2021-2032)
- 6.2 Global Remicade (Infliximab) and Biosimilar Revenue by Type (2021-2032)
- 6.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Type (2021-2032)
- 6.3 Global Remicade (Infliximab) and Biosimilar Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2021-2032)
- 7.1.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Remicade (Infliximab) and Biosimilar Sales Market Share by Application (2021-2032)
- 7.2 Global Remicade (Infliximab) and Biosimilar Revenue by Application (2021-2032)
- 7.2.1 Global Remicade (Infliximab) and Biosimilar Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Remicade (Infliximab) and Biosimilar Revenue Market Share by Application (2021-2032)
- 7.3 Global Remicade (Infliximab) and Biosimilar Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Remicade (Infliximab) and Biosimilar Value Chain Analysis
- 8.1.1 Remicade (Infliximab) and Biosimilar Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Remicade (Infliximab) and Biosimilar Production Mode & Process
- 8.2 Remicade (Infliximab) and Biosimilar Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Remicade (Infliximab) and Biosimilar Distributors
- 8.2.3 Remicade (Infliximab) and Biosimilar Customers
9 Global Remicade (Infliximab) and Biosimilar Analyzing Market Dynamics
- 9.1 Remicade (Infliximab) and Biosimilar Industry Trends
- 9.2 Remicade (Infliximab) and Biosimilar Industry Drivers
- 9.3 Remicade (Infliximab) and Biosimilar Industry Opportunities and Challenges
- 9.4 Remicade (Infliximab) and Biosimilar Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst